Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06589245 · ClinicalTrials.gov registry record · Phase 1
Inhaled Ciclesonide Study in Preterm Infants
A Phase 1 study of Bronchopulmonary Dysplasia, sponsored by Venkatesh Sampath.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06589245: Recruiting Phase 1 study of Bronchopulmonary Dysplasia, sponsored by Venkatesh Sampath.
NCT06589245 is a Phase 1 study of Bronchopulmonary Dysplasia that is actively recruiting participants, run by Venkatesh Sampath. The registered enrollment target is 30 participants, below the 235-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06589245, a Phase 1 study of Bronchopulmonary Dysplasia, is actively recruiting participants, sponsored by Venkatesh Sampath.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR, in blood cells).
Primary Outcome
Blood Glucose (BG) levels will be collected 24 hours prior to initiation of study drug and then every 12 hours after initiation of study drug for 2 weeks. BG will be monitored daily for a week after cessation of drug treatment and as per NICU protocol thereafter.
Conditions Studied
Interventions
- DRUG Alvesco Inhalant Product
Study Locations (1)
Missouri
- Children's Mercy Kansas City - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 1 |
What NCT06589245 shows while recruiting
NCT06589245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 235-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Bronchopulmonary Dysplasia appearing as the primary indexed condition, and to 1 intervention - of which Alvesco Inhalant Product is the first listed.
NCT06589245 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06589245 about?
NCT06589245 is a clinical study titled "Inhaled Ciclesonide Study in Preterm Infants". Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR...
What is the current status of trial NCT06589245?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-16. Estimated completion is 2026-08-31.
What conditions does trial NCT06589245 study?
This clinical trial studies the following conditions: Bronchopulmonary Dysplasia.
What interventions are being tested in trial NCT06589245?
The interventions under investigation include: Alvesco Inhalant Product (DRUG).
Who is sponsoring clinical trial NCT06589245?
This trial is sponsored by Venkatesh Sampath, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06589245 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchopulmonary Dysplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06589245's enrollment target sits among peer trials
30 25th of 29 higher than 5 of 29 other Bronchopulmonary Dysplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchopulmonary Dysplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Montelukast in Very Low Birthweight Infants
COMPLETED · Phase 1
-
Delivery Room CPAP in Extremely Low Birth Weight Infants
COMPLETED · Phase 1
-
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
RECRUITING · NA
-
Multidimensional Phenotype Classification in Grade 3 Bronchopulmonary Dysplasia
RECRUITING
-
Genesis Electrical Impedance Tomography (EIT): A Preliminary Study
RECRUITING
-
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI